Summary - Funding Rounds

Founding Date

1987

Total Funding

$29.5 m
In total, Repros Therapeutics had raised $29.5 m. Repros Therapeutics is a subsidiary of Allergan

Repros Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

9.0k9.0k11.0k47.0k

Revenue growth, %

22%(55%)

R&D expense

23.7m27.1m24.1m12.8m

General and administrative expense

4.8m5.4m5.1m4.6m

Operating expense total

28.5m32.5m29.2m17.3m

Interest income

47.0k

Net Income

(27.7m)(32.5m)(29.2m)(17.3m)

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

2.0k2.0k2.0k1.0k1.0k1.0k17.0k15.0k10.0k7.0k

R&D expense

7.3m7.5m6.1m7.3m6.5m5.5m3.8m3.2m3.2m2.1m

General and administrative expense

1.2m1.3m1.3m1.2m1.3m1.1m1.1m1.1m997.0k3.8m

Operating expense total

8.6m8.7m7.4m8.5m7.8m6.6m4.9m4.3m4.2m5.9m

Interest income

2.0k2.0k2.0k1.0k1.0k1.0k17.0k15.0k10.0k7.0k

Net Income

(8.5m)(8.7m)(7.4m)(8.5m)(7.8m)(6.6m)(4.8m)(4.3m)(4.2m)(5.9m)

Repros Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

75.8m46.6m21.4m8.7m

Accounts Receivable

1.1m

Inventories

189.0k289.0k84.0k

Current Assets

76.0m46.9m21.5m8.8m

PP&E

75.0k8.0k

Total Assets

79.0m46.9m21.5m8.8m

Accounts Payable

3.0m2.1m2.0m1.9m

Short-term debt

Current Liabilities

3.6m2.9m2.9m2.7m

Long-term debt

Total Debt

Additional Paid-in Capital

314.4m318.4m322.2m327.0m

Retained Earnings

(273.1m)(302.3m)(319.5m)

Total Equity

75.4m44.0m18.6m6.1m

Financial Leverage

1 x1.1 x1.2 x1.4 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

68.0m60.7m53.1m37.9m32.2m26.2m16.0m12.5m10.5m3.2m

Current Assets

68.6m61.0m53.3m38.4m32.6m26.5m16.3m12.8m10.7m4.5m

PP&E

64.0k42.0k11.0k6.0k5.0k4.0k2.0k

Total Assets

71.8m64.3m56.8m38.5m32.6m26.5m16.3m12.8m10.7m5.4m

Accounts Payable

3.4m3.7m2.6m1.2m2.2m1.8m1.6m1.6m1.8m1.7m

Current Liabilities

3.9m4.1m3.0m2.0m2.9m2.5m2.1m2.3m2.3m2.8m

Total Liabilities

3.8m

Additional Paid-in Capital

315.4m316.4m317.4m319.5m320.5m321.4m322.7m323.2m325.3m328.4m

Retained Earnings

(281.6m)(289.4m)(296.0m)(307.1m)(311.4m)(315.5m)(325.4m)

Total Equity

67.9m60.2m53.8m36.5m29.7m24.0m14.2m10.5m8.4m1.6m

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.3 x3.3 x

Repros Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(27.7m)(32.5m)(29.2m)(17.3m)

Depreciation and Amortization

257.0k43.0k24.0k5.0k

Accounts Receivable

Inventories

Accounts Payable

Cash From Operating Activities

(24.4m)(29.3m)(25.3m)(15.6m)

Cash From Investing Activities

(911.0k)

Short-term Borrowings

Cash From Financing Activities

77.0m147.0k102.0k2.9m

Free Cash Flow

(24.5m)(25.3m)(15.6m)

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(8.5m)(8.7m)(24.6m)(8.5m)(7.8m)(22.9m)(4.8m)(9.1m)(13.3m)(5.9m)

Depreciation and Amortization

58.0k270.0k21.0k2.0k3.0k4.0k1.0k

Accounts Payable

3.7m2.6m1.2m2.2m1.8m1.6m1.6m1.8m1.7m

Cash From Operating Activities

(7.6m)(22.0m)(20.5m)(5.3m)(8.9m)(12.5m)(4.6m)

Cash From Investing Activities

(285.0k)(828.0k)

Cash From Financing Activities

104.0k147.0k102.0k1.6m997.0k